The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Sirolimus‐based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma†
Open accessAbstract
UNLABELLED: Liver transplantation is an important treatment option for selected patients with nonresectable hepatocellular carcinoma (HCC). Several reports have suggested a lower risk of posttransplant tumor recurrence with the use of sirolimus and a higher one with calcineurin inhibitors, but the selection of an ideal immunosuppression protocol is still a matter of debate. The aim of this study was to define the immunosuppression associated with the best survival after liver transplantation for HCC. It was based on the Scientific Registry of Transplant Recipients and included 2,491 adult recipients of isolated liver transplantation for HCC and 12,167 for non-HCC diagnoses between March 2002 and March 2009. All patients remained on stable maintenance immunosuppression protocols for at least 6 months posttransplant. In a multivariate analysis, only anti-CD25 antibody induction and sirolimus-based maintenance therapy were associated with improved survivals after transplantation for HCC (hazard ratio [HR] 0.64, 95% confidence interval [CI]: 0.45-0.9, P < or = 0.01; HR 0.53, 95% CI: 0.31-0.92, P < or = 0.05, respectively). The other studied drugs, including calcineurin inhibitors, did not demonstrate a significant impact. In an effort to understand whether the observed effects were due to a direct impact of the drug on tumor or more on liver transplant in general, we conducted a similar analysis on non-HCC patients. Although anti-CD25 induction was again associated with a trend toward improved survival, sirolimus showed a trend toward lower rates of survival in non-HCC recipients, confirming the specificity of its beneficial impact to cancer patients. CONCLUSION: According to these data, sirolimus-based immunosuppression has unique posttransplant effects on HCC patients that lead to improved survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mazzaferro, V., Regalia, E., Doci, R., Andreola, S., Pulvirenti, A., Bozzetti, F., Montalto, F., Ammatuna, M., Morabito, A., & Gennari, L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341104 · Cited by 7,186
Mazzaferro, V., Llovet, J. M., Miceli, R., Bhoori, S., Schiavo, M., Mariani, L., Camerini, T., Roayaie, S., Schwartz, M. E., Grazi, G. L., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70284-5 · Cited by 2,045
Guba, M., von Breitenbuch, P., Steinbauer, M., Koehl, G., Flegel, S., Hornung, M., Bruns, C. J., Zuelke, C., Farkas, S., Anthuber, M., et al. (2002) · Nature Medicine · doi:10.1038/nm0202-128 · Cited by 1,739
PRO- AND ANTI-CANCER EFFECTS OF IMMUNOSUPPRESSIVE AGENTS USED IN ORGAN TRANSPLANTATION
Guba, M., Graeb, C., Jauch, K.-W., & Geissler, E. K. (2004) · Transplantation · doi:10.1097/01.tp.0000120181.89206.54 · Cited by 360
Toso, C., Asthana, S., Bigam, D. L., Shapiro, A. M. J., & Kneteman, N. M. (2009) · Hepatology · doi:10.1002/hep.22693 · Cited by 332
Self-citationNeuberger, J. M., Mamelok, R. D., Neuhaus, P., Pirenne, J., Samuel, D., Isoniemi, H., Rostaing, L., Rimola, A., Marshall, S., & Mayer, A. D. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2008.02493.x · Cited by 289
Harnois, D. (2009) · Yearbook of Gastroenterology · doi:10.1016/s0739-5930(09)79363-8 · Cited by 268
Kneteman, N. M., Oberholzer, J., Al Saghier, M., Meeberg, G. A., Blitz, M., Ma, M. M., Wong, W. W. S., Gutfreund, K., Mason, A. L., Jewell, L. D., et al. (2004) · Liver Transplantation · doi:10.1002/lt.20237 · Cited by 256
Self-citationVivarelli, M., Cucchetti, A., Barba, G. L., Ravaioli, M., Del Gaudio, M., Lauro, A., Grazi, G. L., & Pinna, A. D. (2008) · Annals of Surgery · doi:10.1097/sla.0b013e3181896278 · Cited by 236
Toso, C., Trotter, J., Wei, A., Bigam, D. L., Shah, S., Lancaster, J., Grant, D. R., Greig, P. D., Shapiro, A. M. J., & Kneteman, N. M. (2008) · Liver Transplantation · doi:10.1002/lt.21484 · Cited by 230
Self-citation
Cited by
Llovet, J. M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., & Gores, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.18 · Cited by 2,531
Geissler, E. K., Schnitzbauer, A. A., Zülke, C., Lamby, P. E., Proneth, A., Duvoux, C., Burra, P., Jauch, K.-W., Rentsch, M., Ganten, T. M., et al. (2016) · Transplantation · doi:10.1097/tp.0000000000000965 · Cited by 433
Self-citationAutophagy in chronic liver diseases: the two faces of Janus
Gual, P., Gilgenkrantz, H., & Lotersztajn, S. (2017) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00295.2016 · Cited by 91
Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go?
De Bruyn, P., Van Gestel, D., Ost, P., Kruse, V., Brochez, L., Van Vlierberghe, H., Devresse, A., del Marmol, V., Le Moine, A., & Aspeslagh, S. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000505 · Cited by 79
Metadata
- Authors
- Toso, C., Merani, S., Bigam, D. L., Shapiro, A. M. J., & Kneteman, N. M.
- Venue
- Hepatology
- Published
- 2010-04
- Volume
- 51
- Issue
- 4
- Pages
- 1237-1243
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2061059105
- Cited by
- 329
- References
- 18
- FWCI
- 18.24
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sirolimus‐based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma†. https://app.cochat.ai/papers/10.1002/hep.23437
- The paper
- Toso, C., Merani, S., Bigam, D. L., Shapiro, A. M. J., & Kneteman, N. M. (2010). Sirolimus‐based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma†. Hepatology. https://doi.org/10.1002/hep.23437
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
